|
Market Closed -
Nasdaq
16:00:00 2026-10-16 EDT
|
5-day change | 1st Jan Change | ||
| 157.14 USD | -2.87% |
|
-6.66% | -13.96% |
| 10-14 | Axsome Shows Valuation Disconnect Ahead of Q3, RBC Says | MT |
| 10-08 | RBC Trims Price Target on Axsome Therapeutics to $295 From $297, Keeps Outperform Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| AXSOME THERAPEUTICS, INC. | Biopharmaceuticals | -2.87% | -6.66% | -13.96% | +25.71% | +291.87% | 8.23B |  | |  |
- Stock Market
- Stocks
- AXSM Stock
- Charts Axsome Therapeutics, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
